Health and Healthcare

All Health and Healthcare Articles

Newest first · Page 339

Biotech IPO Filing: Aldagen, Inc. (ALDH)

We have just seen a biotech company named Aldagen, Inc. file for an initial public offering of common stock.  This will trade under the proposed stock ticker “ALDH” on NASDAQ.  The company is developing…

Douglas A. McIntyre · 17 years ago

Two IPOs On Deck (ADUS, VSI, BX)

We have two initial public offerings today.  We have a poor pricing from Addus HomeCare Corporation (NASDAQ: ADUS) and a solid pricing from a Blackstone interest in the Vitamin Shoppe Inc. (NYSE: VSI) IPO.…

Douglas A. McIntyre · 17 years ago

Amgen (AMGN) Earnings Bump Up

Amgen (NASDAQ:AMGN) had a strong quarter. Biotech has been the most active part of the market in terms of trading volume. Amgen is the category’s grandfather. The company reported EPS of $1.49 for the…

Douglas A. McIntyre · 17 years ago

AGA Medical Debuts During Cautious IPO Market (AGAM)

It was just over the weekend that we noted how cautious the initial public offering market has become.  What a difference a couple months can make.  Today marks the debut of AGA Medical Holdings,…

Douglas A. McIntyre · 17 years ago

Pfizer (PFE) Earns OK

Pfizer (NYSE:PFE) had a better quarter than many expected. The drug company reported financial results for third-quarter 2009. Revenues were $11.6 billion, a decrease of 3%. EPS fell to $.51 from $.62 on an…

Douglas A. McIntyre · 17 years ago

Palomar Dumped by J&J (PMTI, JNJ)

Palomar Medical Technologies Inc. (NASDAQ: PMTI) is getting hit very hard.  The company issued a press release saying “Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson.” …

Douglas A. McIntyre · 17 years ago

Specter of MRI Disease Haunts GE

by Jeff Gerth, ProPublica In May 2006, medical regulators in Denmark issued a warning that signaled trouble for General Electric (NYSE:GE). Danish researchers noted that, over a four-year period, 25 patients in Denmark and…

Douglas A. McIntyre · 17 years ago

Flu Drug Sales Take Off

Roche earnings offered hope to the scores of biotech companies working on H1N1 treatments. The big pharma firm, which makes most of its money from cancer treatments, profited from the spread of the flu. Roche…

Douglas A. McIntyre · 17 years ago

52-Week High Club

Pier 1 Imports Inc. (NYSE: PIR) rallied over 11% to a yearly high of $5.01 after Dow Jones reported that the company had entered into an agreement to sell its St. Charles Ill. distribution…

Douglas A. McIntyre · 17 years ago

Potential Breakthrough in Esophagus Cancer (CTIC)

Cell Therapeutics, Inc. (NASDAQ: CTIC) has announced what may be a large breakthrough in the fight against cancer.  This is a combined test rather than as a standalone treatment, but the result may be…

Douglas A. McIntyre · 17 years ago

Is Sequenom Dead? (SQNM)

Sequenom Inc. (NASDAQ: SQNM) is becoming a case study on how to run a medical testing products company into the ground.  The diagnostic test maker has more problems other than just the announcement that…

Douglas A. McIntyre · 17 years ago

Still No Death Blow for Insurers (AET, HUM, UNH)

The Obama speech to a joint session of Congress last night did not exactly deliver the death blow to health insurers.  It also did not give the insurers the keys to the palace.  Despite…

Douglas A. McIntyre · 17 years ago

BioTech Hostile Takeover: Biogen Plays For Facet

Facet Biotech Corporation (FACT) confirms that it is in receipt of Biogen Idec Inc.’s (BIIB) letter dated September 4, 2009 offering $14.50 per share for all of the outstanding shares of Facet. Facet shares…

Douglas A. McIntyre · 17 years ago